ARGX-121 / argenx - LARVOL DELTA

Verdant: A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: argenx

New P2 trial • Glomerulonephritis • IgA Nephropathy • Renal Disease

Phase 1 study for ARGX-109 expected to complete by end of 2025; Phase 1 studies for ARGX-213 and ARGX-121 expected to complete in first half of 2026 (argenx Press Release)

Trial completion date • Immunology

Advance four new pipeline molecules and generate sustainable value through continued investment in Immunology Innovation Program (GlobeNewswire) - "argenx continues to invest in its Immunology Innovation Program (IIP) to drive long-term sustainable pipeline growth. Through the IIP, four new pipeline candidates have been nominated, including: ARGX-213, targeting FcRn and further solidifying argenx’s leadership in this biology; ARGX-121, a first-in-class molecule targeting IgA; ARGX-109, targeting IL-6, which plays an important role in inflammation, and a fourth pipeline candidate, a first-in-class sweeping antibody for which the target has not yet been disclosed....Phase 1 results from ongoing ARGX-109 study expected in second half of 2025, and from ongoing ARGX-213 and ARGX-121 studies expected in first half of 2026."

P1 data • Pipeline update • Immunology • Inflammation

Advance four new pipeline molecules and generate sustainable value through continued investment in Immunology Innovation Program (GlobeNewswire) - "argenx continues to invest in its Immunology Innovation Program (IIP) to drive long-term sustainable pipeline growth. Through the IIP, four new pipeline candidates have been nominated, including: ARGX-213, targeting FcRn and further solidifying argenx’s leadership in this biology; ARGX-121, a first-in-class molecule targeting IgA; ARGX-109, targeting IL-6, which plays an important role in inflammation, and a fourth pipeline candidate, a first-in-class sweeping antibody for which the target has not yet been disclosed. Phase 1 results from ongoing ARGX-109 study expected in second half of 2025, and from ongoing ARGX-213 study and ARGX-121 study expected in first half of 2026."

Clinical data • Pipeline update • Immunology

argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update (GlobeNewswire) - "argenx continues to invest in its Immunology Innovation Program (IIP) to drive long-term sustainable pipeline growth. Through the IIP, four new pipeline candidates have been nominated, including: ARGX-213, targeting FcRn and further solidifying argenx’s leadership in this new class of medicine; ARGX-121, a first-in-class molecule targeting IgA; ARGX-109, targeting IL-6, which plays an important role in inflammation, and ARGX-220, a first-in-class sweeping antibody for which the target has not yet been disclosed. Phase 1 studies of ARGX-213 and ARGX-121 expected to start in second half of 2025; Investigational new drug (IND) applications for ARGX-220 and ARGX-109 on track to be filed by end of 2025..."

IND • New P1 trial • Pipeline update • Immunology • Inflammation